Moderna, Inc. (MRNA) 今日盘中股价大幅上涨7.97%，引起了市场的广泛关注。
消息面上，Moderna公布的2025年第四季度财务业绩表现强劲，营收达到6.78亿美元，超出了市场分析师平均预期的6.261亿美元，这主要得益于其新冠疫苗在美国的销售好于预期。同时，公司重申了2026年营收同比增长10%的业绩指引，并预期美国市场与国际市场将各贡献约50%的营收，展现了均衡的全球化布局。此外，公司高管透露正积极争取其流感与新冠联合疫苗在年内获得欧洲监管机构的批准，为未来的收入增长提供了潜在催化剂。
这些积极的财务数据和业务进展共同增强了投资者对公司短期业绩韧性与长期增长前景的信心，从而推动了股价在盘中交易时段显著上扬。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.